9
Participants
Start Date
December 31, 2011
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
MUC1 Dendritic Cell Vaccine (Cvac)
"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
Greenslopes Private Hospital, Greenslopes
Collaborative Research Group, Boca Raton
Indiana University Simon Cancer Center, Indianapolis
Scripps Cancer Center, La Jolla
Marin Cancer Care, Inc., Greenbrae
University of Washington Medical Center, Seattle
Lead Sponsor
Prima BioMed Ltd
INDUSTRY